Engineered immune cells take on lupus and other autoimmune diseases
NCT ID NCT07174843
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 35 times
Summary
This early-stage study tests a new treatment called BZE2204, which uses a patient's own immune cells modified to target and attack faulty immune cells causing autoimmune diseases. It is for 20 adults with lupus, idiopathic inflammatory myopathies, or immune thrombocytopenia that have not responded to standard treatments. The main goals are to check safety and see if the therapy can control disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Mengchao Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200240, China
Contact
Conditions
Explore the condition pages connected to this study.